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Abstract
Background: The objective of Heart Health NOW (HHN) is to determine if primary care practice support—a
comprehensive evidence-based quality improvement strategy involving practice facilitation, academic detailing,
technology support, and regional learning collaboratives—accelerates widespread dissemination and implementation
of evidence-based guidelines for cardiovascular disease (CVD) prevention in small- to medium-sized primary care
practices and, additionally, increases practices’ capacity to incorporate other evidence-based clinical guidelines in the
future.
Methods/design: HHN is a stepped wedge, stratified, cluster randomized trial to evaluate the effect of primary care
practice support on evidence-based CVD prevention, organizational change process measures, and patient outcomes.
Each practice will start the trial as a control, receive the intervention at a randomized time point, and then enter a
maintenance period 12 months after the start of the intervention. The intervention will be randomized to practices in
one of four strata defined by region of the state (east or west) and degree of practice readiness for change.
Seventy-five practices in each region with a high degree of readiness will be randomized 1:1:1 in blocks of
3 sometime prior to month 8 to receive the intervention at month 9, 11, or 12. An additional 75 practices
within each region that have a low degree of readiness or are recruited later will be randomized 1:1 in
blocks of 2 prior to month 13 to receive the intervention at month 14 or 16. The sites will be ordered within
each strata based on time of enrollment with the blocking based on this ordering. Evaluation will examine
the effect of primary care practice support on (1) practice-level delivery of evidence-based CVD prevention,
(2) patient-level health outcomes, (3) practice-level implementation of clinical and organizational changes that
support delivery of evidence-based CVD prevention, and (4) practice-level capacity to implement future
evidence-based clinical guidelines.
Discussion: Results will indicate whether primary care practice support is an effective strategy for widespread
dissemination and implementation of evidence-based clinical guidelines in primary care practices. Discernible
reductions in cardiovascular risk in 300 practices covering over an estimated 900,000 adult patients would
likely lead to prevention of thousands of cardiovascular events within 10 years.
Trial registration: ClinicalTrials.gov NCT02585557
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Background
Cardiovascular disease (CVD) is the leading cause of death
in the USA [1]. CVD imposes a staggering burden
whether measured in life-years lost, diminished quality of
life, racial and ethnic health disparities, or direct and indir-
ect healthcare costs. Yet, the Centers for Disease Control
and Prevention (CDC) estimates that more than 200,000
deaths from heart disease and stroke could be prevented
each year through a concerted, national effort to control
CVD risk factors such as blood pressure, cholesterol, and
tobacco use.
In September 2011, the US Department of Health
and Human Services launched the “Million Hearts”
initiative to prevent 1 million heart attacks and
strokes by 2017 [2]. In the clinical realm, Million
Hearts focuses on the management of the “ABC-
S”—aspirin use in high-risk individuals, blood pres-
sure control, cholesterol management, and smoking
cessation [2]. To support Million Hearts, the US
Agency for Healthcare Research and Quality (AHRQ)
launched an initiative in 2015 to assist primary care
practices in implementing clinical and organizational
changes to improve the management of ABCS.
Objectives and aims
Heart Health NOW (HHN), an AHRQ-funded demon-
stration and evaluation, investigates whether a compre-
hensive evidence-based quality improvement strategy
(which we call primary care practice support) accelerates
the implementation of evidence-based guidelines for CVD
prevention in primary care practices on a large scale. The
specific aims are to evaluate the effect of primary care
practice support in small- to medium-sized practices on
(1) practice-level delivery of evidence-based CVD preven-
tion, (2) patient-level health outcomes, (3) practice-level
implementation of clinical and organizational changes that
support delivery of evidence-based CVD prevention, and
(4) practice-level capacity to implement future evidence-
based clinical guidelines. HHN is a cooperative effort of
the University of North Carolina at Chapel Hill (UNC-
CH), the North Carolina Area Health Education Center
(NC AHEC), and Community Care of North Carolina




North Carolina is the tenth largest state in the USA with
a population approaching 10 million and a racial and
ethnic composition of 72 % white, 22 % black, and 9 %
Hispanic [3]. The burden of cardiovascular disease in
North Carolina remains large. The cardiovascular death
rate was 263 per 100,000 as measured in 2008–2010,
accounting for almost one-third of deaths in the state.
These data rank North Carolina 32nd among the 50
states for cardiovascular outcomes [4].
Research design
HHN is a stepped wedge, stratified, cluster randomized
trial. Each practice will start the trial as a control, receive
the primary care practice support intervention at a ran-
domized time point, and then enter a maintenance
period 12 months after the start of the intervention. The
intervention will be randomized to practices in one of
four strata defined by region of the state (east or west)
and degree of practice readiness for change (described
below). Specifically, 75 practices in each region with a
high degree of readiness will be randomized 1:1:1 in
blocks of 3 prior to month 8 to receive the intervention
at month 9, 11, or 12. An additional 75 practices within
each region that have a low degree of readiness or are
recruited later will be randomized 1:1 in blocks of 2
prior to month 13 to receive the intervention at month
14 or 16. The sites will be ordered within each stratum
based on time of enrollment with the blocking based on
this ordering. The study’s statistician will generate the
stratified permuted-block random allocation lists using a
computer program. As practices are enrolled, the project
management system will use the randomization schedule
to randomize practices and assign their intervention
start date. A practice is considered randomized once an
intervention start date has been assigned. Neither study
personnel nor participating practices will be blind to
randomized start dates.
Practice recruitment
We will recruit 300 small- to medium-sized primary care
practices. To be eligible, practices must have ten or
fewer providers in a single location and have an elec-
tronic health record (EHR). Enrolling practices agree to
the following: (1) form a quality improvement team; (2)
meet with the practice facilitator up to 8 h a month; (3)
send representatives to regional learning collaboratives
three times yearly; (4) meet with experts to discuss CVD
prevention, CVD risk assessment, and system change
strategies; (5) permit the CCNC Informatics Center to
process EHR data and provide the practice with cardiovas-
cular care registries and dashboards for clinical decision
support and population health management; (6) review
data on ABCS measures at least monthly; and (7) use
those data to plan, conduct, and assess improvement
activities. Enrolling practices complete an information
technology and quality improvement readiness assess-
ment, which is used for earlier randomization of high-
readiness practices and assignment of practices to more or
less intensive practice facilitation.
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Primary care practice support intervention
Practice facilitators will work for 12 months with prac-
tices’ quality improvement teams to implement four “key
drivers” for supporting delivery of evidence-based CVD
prevention: enhanced clinical information systems with
dashboards on critical measures and drill downs to
patient-level care; adoption and use of practice-wide
evidence-based protocols; effective use, documentation,
and tracking of patient self-management support goals;
and optimization of the practice care team. Practices will
receive up to 8 h a month of practice facilitation
depending on their level of readiness at enrollment. In
addition, physician faculty will engage in academic
detailing through webinars and practice visits. Detailing
will focus on CVD prevention and treatment, CVD risk
assessment, and new recommendations for cholesterol
and hypertension management. Finally, providers and
staff will participate in regional learning collaborative
meetings where they can share experiences implement-
ing evidence into practice.
Evaluation framework
Our evaluation draws on an organizational model of
innovation implementation [5–9]. The innovation here
is evidence-based CVD prevention (including clinical
decision support and population health management
tools, global risk-based treatment of lipids, new treatment
options, and evidence-based smoking cessation). Briefly,
effective implementation is a function of the implementa-
tion support the practice receives and the policies and
practices it employs to support innovation use (see Fig. 1).
Practice capacity for QI, readiness for change, and imple-
mentation climate moderate the relationship between sup-
port, policies and procedures, and effectiveness. Inner and
outer contextual factors influencing organizational prior-
ities, capabilities, and opportunities also moderate the
relationship. Realization of patient- and practice-level ben-
efits depends on effective implementation of evidence-
based CVD prevention.
Data collection
Table 1 outlines data collection, measures, sources, and
timing for each construct.
Practice facilitator contact logs
Practice facilitators (PFs) will record monthly the fre-
quency, duration, and mode of practice contact. We will
use these data to measure the intensity of implementa-
tion support provided to practices.
Fig. 1 Conceptual framework guiding the evaluation of Heart Health Now
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Academic detailing logs
Physician faculty will record visits, calls, and other con-
tacts with practices. Webinar software will track logins
and pages viewed by practice staff.
Regional collaborative attendance records
Project staff will keep records of the number and types
of staff from each practice that attend regional collab-
orative meetings.
Key informant surveys
We will survey key informants (KIs) to assess practice
capacity for QI, inner context, and outer context. The sur-
veys will be administered at baseline, end-of-intervention,
6 months post-intervention, and 12 months post-
intervention for practices enrolled earlier in the study.
The KI will be the practice’s provider champion (N = 300).
Provider/staff survey
We will survey providers and staff to assess practice cap-
acity for QI at baseline, end-of-intervention, 6 months
post-intervention, and 12 months post-intervention for
practices enrolled earlier; organizational readiness to im-
plement change at baseline; and implementation climate
at end-of-intervention and 6 months post-intervention.
The sample will consist of 3–5 providers and staff mem-
bers depending on practice size (N = 900–1500).
PF ratings
PFs will assess on a monthly basis practices’ progress in
implementing clinical practice and organizational changes
to support improvement in CVD prevention (implementa-
tion policies and practices). Ratings will focus on the ex-
tent to which practices have implemented four key drivers
of improved CVD prevention and also level of leadership
and team engagement.
Interviews
We will conduct semi-structured KI interviews (N = 300)
at end-of-intervention and 6 months post-intervention
to obtain supplemental data about organizational changes
for evidence-based CVD prevention (implementation pol-
icies and practices) and influential inner and outer context
events. The KI interview at end-of-intervention will also
ask about acceptability of the implementation support re-
ceived (implementation effectiveness). The KI interview
6 months post-intervention will ask about practice-level
outcomes (innovation effectiveness).
Table 1 Theoretical constructs, measures, data sources, and data collection timing
Construct Measures Source Timing
Implementation support Frequency, duration, and mode of PF contacts PF contact logs I
Frequency, duration, and mode of academic
detailing contact
Contact, webinar logs I
Attendance at regional collaborative meetings Attendance logs I
Practice capacity for QI Change Process Capacity Questionnaire KI survey B, E, F
Adaptive Reserve Questionnaire Provider/staff survey B, E, F
Organizational readiness Organizational Readiness for Change Questionnaire
(ORIC)
Provider/staff survey B
Implementation Policies and Practices (IPPs) Key Driver Implementation Scales PF Ratings I
Implementation barriers, facilitators, and IPPs KI interview B, E
Implementation climate Implementation climate questionnaire Provider/staff survey E, F
Implementation effectiveness ABCS measures/clinical measures HIE B, I, E, F
Acceptability of implementation support KI interview E
Innovation effectiveness Patient outcomes (communication, shared
decision-making)
Patient survey B, E
Patient outcomes (healthcare utilization and
mortality)
Claims data B, E, F
Practice outcomes (e.g., financial benefits) KI Interview E, F
Inner context Practice characteristics, patient population, EMR
capabilities
KI survey, PF contact logs B, E,F
Outer context External policies and incentives, market conditions KI survey, KI interview, PF contact logs B, E, F
Because readiness is conceived as an organization-level construct, we will test whether sufficient inter-rater reliability and inter-rater agreement exist to aggregate
individual responses to the practice level [22–26]. If tests do not justify aggregation, we will use a measure of intra-practice variability in readiness rather than a
practice-level mean in our analysis [15, 16].
Source: PF practice facilitator, KI key informant; timing: B baseline, I intervention, E end of intervention, F 6 and 12 months post-intervention
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EHR/informatics
We will obtain performance data on the ABCS measures
(implementation effectiveness) and patients’ intermedi-
ate clinical outcomes (innovation effectiveness) from the
EHR. The ABCS measures and clinical outcomes will be
collected at baseline, during the intervention (quarterly),
at the end of the intervention, and post-intervention (6
and 12 months follow-up). The EHR will also supply
race/demographic data. EHR data will be routed to the
CCNC Informatics Center, where the data will be ex-
tracted, normalized, and placed in a standard report
used for the evaluation and sent back to the practices.
Patient surveys
We will survey 200 consecutive adult patients in each
practice at baseline and at the end of the intervention
to obtain patient experience data on communication
and shared decision-making (innovation effectiveness).
Data will be collected during an office visit using
paper-based surveys. Eligible patients must have one
or more of the following comorbidities: hypertension/
high blood pressure, myocardial infarction/heart attack,
angina/coronary heart disease, stroke, smoking, diabetes,
and high cholesterol.
Claims data
We will use claims data at baseline, end-of-intervention,
and 6 months post-intervention to assess hospitaliza-
tions for cardiovascular-related conditions, in-hospital
deaths, and mortality for patients seen at participating
practices (innovation effectiveness). We will have access
to claims data on 85 % of the insured population in NC,
specifically those covered by Blue Cross Blue Shield of
North Carolina, the State Employee Health Plan,
Medicare, and Medicaid. Outcomes will be aggregated
to the practice level. For the baseline period, we will
examine claims data for the year prior to the intervention.
Following the intervention, we will examine available
claims during and after the intervention for each practice.
Measures
Implementation support. We will measure primary care
practice support intensity as the percentage of contacts
with a practice that are in-person. We will also report
the actual number of in-person contacts and number of
total contacts to account for variability in contacts
across practices. We will also track frequency, mode,
and duration of contact with academic detailers, as well
as number and type of staff per practice attending col-
laborative meetings.
Practice capacity for QI encompasses two constructs.
The first construct, change process capability, refers to a
“state of preparedness for change that is influenced by
the organization’s previous history of change, its plans
for continuous organizational refinement, and its ability
through its social and technical systems to initiate and
sustain that change” ([10], p. 193). We will measure this
construct using the Change Process Capacity Question-
naire (CPCQ) [10]. The second construct, adaptive
reserve, refers to “the practice relationship infrastructure;
alignment of management functions in which clinical care,
practice operations, and financial functions and reflect a
consistent vision; facilitative leadership; teamwork; sense-
making; a positive work environment; and a culture of
learning”([11], p. S37). We will measure this construct
using the Practice Adaptive Reserve scale [11, 12].
Organizational readiness for change refers to the extent
to which organizational members are psychologically and
behaviorally prepared to implement change [6, 7, 13]. We
will measure readiness using the Organizational Readiness
for Implementing Change scale [13].
Implementation policies and practices are the strat-
egies that an organization puts into place to support
innovation use [9, 14]. We will measure implementation
policies and practices using the Key Drivers of Imple-
mentation Scales (KDIS) [15]. PFs will rate the extent of
practice implementation of the four key drivers using a
5-point, behaviorally-anchored scale. Table 2 offers an
example of the KDIS for planned care.
Implementation climate refers to organizational mem-
bers’ “shared summary perception of the extent to which
their use of a specific innovation is rewarded, supported,
and expected within their organization” ([16], p. 1060).
We will measure implementation climate using a 6-item
scale [17].
Implementation effectiveness refers to the consistency
and quality of aggregate or pooled innovation use (e.g.,
evidence-based CVD prevention) [14]. We will assess
implementation effectiveness using nine ABCS measures
(see Table 3).
We will measure acceptability of primary care practice
support qualitatively by asking about KIs’ satisfaction
Table 2 Key Drivers of Implementation Scale (KDIS) for
standardized care processes
Level Description
0 - No activity No activity on standardization.
1 - Protocols identified Practice identifies sample protocols
and customizes them for their practice.
2 - Staff enabled Practice enables staff to perform roles
(via standing orders, etc.) needed to
implement protocols.
3 - Testing workflow Practice is develops/tests workflows to
support protocols.
4 - Implementation Practice implements and follows at least
one protocol.
5 - Full implementation Practice monitors the system to ensure
that protocols are used consistently.
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with the frequency, duration, and quality of implementa-
tion support.
Innovation effectiveness refers to the benefits that result
from innovation use (e.g., patient and practice outcomes)
[14]. To capture patients’ assessment of communication,
we will use selected items from the CAHPS clinician and
group survey (see Table 4) [18].
To capture patients’ assessment of shared decision-
making, we will use selected items from the CAHPS
patient-centered medical home supplement [19] (see
Table 5).
In addition, we will assess patients’ healthcare
utilization and mortality using claims data. We will
measure hospitalizations for stroke, acute myocardial
infarction, and angina identified via primary diagnoses
and in-hospital mortality for these conditions. For pa-
tients covered by Medicare and Medicaid, we will also
be able to assess non-hospital related mortality. We
will also collect clinical data on patients’ blood pres-
sure, cholesterol levels, smoking status, and CVD risk
based on the ASCVD risk calculator developed by the
American Cardiology Foundation and the American
Heart Association (see Table 6). These clinical data
will be extracted and summarized by the CCNC In-
formatics Center.
We will measure practice outcomes qualitatively by ask-
ing whether evidence-based CVD prevention improved
the practice’s standing in a pay-for-performance program,
provided them with maintenance of certification credits,
improved their payments through the BCBS of NC spon-
sored Blue Quality Physicians Program, or made them
more attractive for recruitment into ACOs/Shared Savings
Programs and other global payment programs.
Inner context refers to structural, political, and cultural
features of the practice that are directly related to expe-
riences of patients and staff, as well as features of the
Table 3 Process of care measures for ABCS
Ischemic vascular disease (IVD): use of aspirin or
another antithrombotic
Percentage of patients aged 18 years and older with ischemic vascular disease (IVD) with
documented use of aspirin or other antithrombotic.
Aspirin for the primary prevention of
cardiovascular disease
Percentage of patients between the ages of 50 and 75 with an ASCVD risk score of ≥10 %
who do not currently have ischemic vascular disease with documented aspirin use.
Blood pressure management: controlling high
blood pressure
Percentage of patients aged 18 through 85 years of age with a diagnosis of hypertension (HTN)
whose blood pressure (BP) was adequately controlled (<140/90) during the measurement year.
Blood pressure management: controlling high
blood pressure
Percentage of patients aged 18 through 85 years of age with a diagnosis of HTN whose blood
pressure was adequately controlled ( age 18–59 and/or people with diabetes or chronic kidney
disease <140/90; age 60–85 < 150/90 ) during measurement year.
Statin therapy for prevention and treatment of
cardiovascular disease
Percentage of the following patients—all considered at high risk of cardiovascular events—
who were prescribed or were on statin therapy: adults ages ≥21 years who were previously
diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular
disease (ASCVD); or adults ages ≥21 years with a fasting or direct low-density lipoprotein
cholesterol (LDL-C) level ≥190 mg/dL; or adults ages 40–75 years with a diagnosis of diabetes
with a fasting or direct LDL-C level of 70–189 mg/dL.
Risk-based statin therapy Percentage of patients aged 40 through 79 years of age whose Calculated Risk Score is 10 %
or greater and are on a statin.
Assessment of cardiovascular risk Percentage of patients ages 40–79, with no evidence of prior cardiovascular event, who have
documentation of required elements for cardiovascular risk assessment.
Tobacco use screening Percentage of patients aged 18 years or older who were seen for at least 2 office visits within
12 months and who were queried about tobacco use one or more times within 24 months
PQRS 226 Part A (modified).
Smoking cessation support Percentage of patients aged 18 years and older identified as tobacco users within the past
24 months and seen for at least 2 office visits within 12 months who received cessation
intervention within 24 months PQRS 226 Part B (modified).
The ischemic vascular disease use of aspirin, blood pressure management 1, tobacco use screening, and smoking cessation support measures are PQRS measures
with defined measure specifications [27]. The aspirin for primary prevention, blood pressure management 2, statin for primary prevention, risk-based statin therapy,
and cardiovascular risk assessment measures reflect newer evidence-based guidelines
Table 4 Communication questions
In the last 12 months, how often did your provider Response options
Q14 explain things in a way that was easy
to understand?
•Never
Q15 listen carefully to you? •Sometimes
Q17 give you easy to understand information
about any health questions or concerns?
•Usually
Q18 seem to know about your medical history? •Always
Q19 show respect for what you had to say?
Q20 spend enough time with you?
Items from the Consumer Assessment of Healthcare Providers and Systems
(CAHPS) Clinician and Group Survey [18]
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larger organization (if any) with which a practice is asso-
ciated [20]. We will capture inner context through our
measures of practice capacity for QI, organizational
readiness, and implementation climate. In addition, we
will assess other structural features, such as practice type
(see Table 7).
Outer context refers to features of the economic,
political, and social context within which an organization
resides [20]. Through the KI survey, we will assess the per-
ceived influence of external events using a 3-point Likert
scale (no influence to significant influence). In KI inter-
views, we will explore qualitatively how events rated “2”
(some influence) influenced the practice’s efforts to imple-
ment evidence-based CVD prevention processes of care.
Data analysis
Aim 1: Evaluate the effect of primary care practice support
on delivery of evidence-based CVD prevention
Our primary hypotheses are that primary care practice
support will improve the percentage of patients in a
practice: (a) with ischemic vascular disease who use aspirin
or other antithrombotics; (b) with hypertension who have
adequate blood pressure control; (c) with an LDL test per-
formed who are prescribed a recommended dose of statin
based on risk status; (d) who were screened for tobacco
use and, if identified as a tobacco user, received cessation
counseling and/or pharmacological therapy; and (e) who
receive aspirin for primary prevention based on a 10-year
CVD risk status. Our secondary hypotheses are as follows:
(a) practice capacity for QI, organizational readiness to im-
plement change, implementation climate, and contextual
factors (inner and outer) will moderate the effect of pri-
mary care practice support on evidence-based CVD pre-
vention; and (b) primary care practice support will reduce
race-based disparities in evidence-based CVD prevention.
Statistical analysis
The statistical analysis of the primary outcomes for Aim
1 will be based on a generalized linear mixed model
(GLMM) for longitudinal binomial data at the practice
level. Allowing for the number of patients who are ob-
served within a practice to vary across time, the models
will be estimated by maximizing the pseudo-likelihood,
specifying practices as clusters, and using empirical vari-
ance estimators. For example, the number of hyperten-
sive patients whose blood pressure is under control Yit,
out of Nit hypertensive patients, will follow a binomial
(Nit, πit) distribution where, conditional upon a practice-
specific random intercept bi0 and slope bi1, πit = E(Yit/
Nit|bi0,bi1) is the expected proportion of hypertensive pa-
tients whose blood pressure is controlled within the i-th
practice in the t-th month; t = si (baseline), si + 3, si + 6,
si +9, si + 12, si + 18 (6 month post-intervention follow-
up), and for some practices si + 24 (12 month post-
intervention follow-up). The GLMM is
Logit πitð Þ ¼ β0 þ bi0 þ β1X i1 þ β2X i2
þ β12X i1X i2 þ g1 t;ψð Þ þ bi1t
þ g2 t; λð ÞX it3 þ g3 t; θð ÞX it4 ð1Þ
where Xi1 = 1 indicates east region and 0 for west region;
Xi2 = 1 indicates higher readiness and 0 for lower
Table 5 Shared decision-making questions
In the last 12 months, did you and your provider talk about starting or stopping a prescription medication?
If yes, complete the rest of the questions.
Response options
PCMH7 When you talked about starting or stopping a prescription medicine,
how much did your provider talk about the reasons you might want
to take a medicine?
Not at all, a little, some, a lot
PCMH8 When you talked about starting or stopping a prescription medicine,
how much did your provider talk about the reasons you might NOT
want to take the medicine?
Not at all, a little, some, a lot
PCMH9 When you talked about starting or stopping a prescription medicine,
did your provider ask you what you thought was best for you?
Yes, no
Items from Consumer Assessment of Healthcare Providers and Systems (CAHPS) patient-centered medical home supplement [19]
Table 6 Practice-level patient outcomes
Outcome Measure
Communication Percentage of patients who answered
“always” to all 6 communication questions
Shared decision-making
(SDM)
Percentage of patients who answered
“a lot” and “yes” to all 3 SDM questions.
Hospitalizations Percentage of patients hospitalized for
stroke, MI, angina.
In-hospital mortality Percentage of patients hospitalized for
stroke, MI, angina who died in the hospital.
Blood pressure Percentage of patients with BP <140/90,
<140/90 if 18–59 years, <150/90 if 60–85 years.
Systolic blood pressure Percentage of patients with a SBP <140;
mean (SD), median (IQR) SBP
Diastolic blood Pressure Percentage of patients with DBP < 90;
mean (SD), median (IQR) DBP
Low-density lipoprotein
(LDL) level
Percentage of patients with LDL levels in the
following categories: <100 mg/dL; 100 to
<160 mg/dL; 160 mg/dL or more
10-year CVD Riska Mean (SD), median (IQR) of individuals who
had CVD risk calculated
abased on ACSVD
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readiness stratum; gt(t
*;ψ) is a smooth spline function of
calendar time (t*) for the secular trend corresponding to
the control condition with finite dimensional parameter
ψ; Xit3 = 1 indicates the active (12 months) intervention
period versus 0 otherwise and g2(t; λ) is function for four
piecewise conjoined linear segments each of 3 months
duration with λ being the vector of slope parameters;
Xit4 = 1 is an indicator for the maintenance period versus
0 otherwise and g3(t;θ) is a function for two piecewise
conjoined linear segments the first of 6 months duration
to which all practices will contribute data and the second
6 months durations to which only a subset of practices
will contribute data as determined by the stepped-wedge
design. Finally, bi0 and bi1 are assumed to be bivariately
normal random variables with respective variances σ0
2 and
σ1
2 and covariance σ01. Primary interest is in the treatment
effect describing the log odds of a randomly sampled
patient in a practice having the outcome 12 months post-
intervention relative to the log odds of a randomly sam-
pled patient from the same practice having the outcome
during the pre-intervention period; this log odds ratio is
well-defined as a function of λ parameters. Finally, the
average causal effect of 12 months of intervention will be
calculated as the average difference in proportions,
Σi[E(Yit/Nit|bi0,bi1,t = si + 12)—E(Yit/Nit|bi0,bi1t = si)]/300; a
95 % confidence interval will be determined by bootstrap-
ping. The random coefficients logistic model (1) will be
fitted using SAS Proc GLIMMIX.
The secondary hypotheses will (a) introduce practice
capacity for QI, organizational readiness to change, im-
plementation climate, and contextual factors as main
effects and effect modifiers in model (1) and introduce
race as a main effect and effect modifier to examine
whether primary care practice support reduces race-
based disparities in the use of evidence-based CVD
prevention. Examination of race will require outcome
data aggregated at the practice level to be broken out
by race.
Statistical power
Power to detect the effect of intervention after 12 months
with respect to the outcome of hypertension control is
simulated for the stepped-wedge study design assuming
300 practices, and an average of μ = 1200 or 1600 patients
per practice (assuming a typical practice has 4 physicians
with 300 or 400 patients per physician). For data collec-
tion months t = si (baseline), si + 3, si + 6, si +9, si + 12, and
si + 18 (6 months post-intervention follow-up), power
calculations are based on practice-month summaries
consisting of 1800 binomial observations (6 × 300).
Power is determined by simulating data from a model
similar to model (1) but, for simplicity, assuming no
temporal trend:
logit E Y it=N itð jbi0; bi1f Þg
¼ β0 þ bi0 þ β2X i2 þ β3X it3 þ bi1t ð2Þ
where Xit3 = 0 if t = si; Xit3 = (t – si)/12 for si < t ≤ si + 12,
and Xit3 = 1 for t = si + 18. This model assumes a linear
logistic trend during the active intervention period and a
constant slope during the maintenance period equal to
the 12-month intervention effect. Additionally, model
(2) specifies a practice-specific intercept and slope as-
sumed to be normally distributed with means 0 and vari-
ances σ0
2 = 0.42, σ1
2 = 0.32 and covariance σ01 = −0.15,
values estimated from preliminary pretest-posttest data
on 19 medical practices (not shown). Primary interest is
in exp(β3), the practice-specific odds ratio of having a
positive outcome (e.g., blood pressure controlled) after
12 months intervention relative to baseline. The number
of patients in the i-th practice assumed to be constant
across time (Ni =Nit for all t) was randomly selected
from Ni ~N(μ, μ
7/4) to account for expected variability
in practice size. A complete data set is then generated
using model (2) with (β0 = 0.50, β2 = 0.05, β3 = 0.05) cor-
responding to a baseline of 62 % blood pressure control
for least ready practices. The fraction of times that H0:
β3 = 0 is rejected with two-sided α = 0.05 Wald tests
under the correctly specified model was taken to be the
simulated power for detecting a non-null odds ratio β3.
When the true β3 = 0, the results represent simulated
type I error, which is seen to be close to the nominal
0.05 significance level. The stepped-wedge design has
excellent power for the outcome, percentage of hyper-
tensive patients with controlled blood pressure (see
Additional file 1).
Table 7 Inner context measures
Practice type Solo, single-specialty, multispecialty
(NAMCS-EMR Q11-13)
Degree of integration Practice owned by physician/group,
HMO, CHC, AMC, other hospital,
other corp. (NAMCS-EMR Q22)
Practice size Number of physicians (NAMCS-EMR
Q12)
Practice staffing Number of mid-level providers
(NAMCS-EMR Q14)
Patient volume Number of office visits in a normal
week (NAMCS-EMR Q10)/per provider
full time equivalent (FTE)
Payer mix Percent patient care revenue from
Medicare, Medicaid, private insurance,
other (NAMCS-EMR Q23)
EMR capabilities Number and use of computerized
capabilities (NAMCS-EMR Q18a-Q18j)
Items from the 2010 National Ambulatory Medical Care Survey electronic
medical records
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Aim 2: Evaluate the effect of primary care practice support
on patient-level health outcomes
Our primary hypotheses are that primary care practice
support will improve the percentage of patients in a prac-
tice who indicate that their provider (a) always communi-
cated well with them during the visit, and (b) involved
them a lot of the times in shared decision-making about
their medications. Our secondary hypotheses are that pri-
mary care practice support will decrease (a) the percent-
age of patients within a practice who were hospitalized for
a cardiovascular disease-related condition, (b) the percent-
age of patients within a practice who were hospitalized for
a cardiovascular disease-related condition or died, and (c)
race-based disparities in CVD-related hospitalizations and
mortality. We will explore whether primary care practice
support improves the percentage of patients in a practice
whose tobacco use status and overall cardiovascular risk
were assessed, whose blood pressure (BP) was adequately
controlled, and who received appropriate management
with regard to aspirin use, tobacco cessation support, and
use of statin therapy.
Statistical analysis
For the primary hypotheses, communication and shared
decision-making are binomial outcomes derived from
patient surveys administered at baseline (t = si) and at
the end of the intervention period (t = si + 12). The
model to assess improvement in these outcomes is a
simplification of model (1) because there are only two
repeated outcomes:
Logit πitð Þ ¼ β0 þ bi0 þ β1X i1 þ β2X i2
þ β12X i1X i2 þ g1 t;ψð Þ þ bi1t
þ β3X it3 ð3Þ
where Xit3 = 1 if t = si + 12 (end-of-intervention period)
and Xit3 = 0 if t = si (baseline). Note that exp(β3) is the
odds ratio of a positive response (e.g., always communi-
cated well, involved them in shared decision-making a
lot of the time) after 12 months of intervention relative
to the odds of a positive response at baseline, controlling
for secular trends via ψ. The average causal effect of
12 months of intervention versus the control condition
will be calculated as the average difference in propor-
tions as described for Aim 1.
For the secondary hypothesis, model (2) will apply to
claims data for the percentage of patients (a) hospital-
ized for a cardiovascular disease-related condition and
(b) hospitalized for a CVD-related condition or died. For
these outcomes, Xit3 = 1 if t = si + 18 (6 months post-
intervention) and Xit3 = 0 if t = si (baseline). To assess
whether primary care practice support decreases race-
based disparities in these outcomes, the binomial data
will be obtained for each race and practice and time
point. Other facility-level patient outcomes are given in
Table 4. Model (3) will be fitted to all binomial outcomes
(e. g., percentage of patients…) using SAS Proc GLIM-
MIX. For continuous outcomes (e.g., a 10-year CVD
Risk), an identity link function leading to a linear model
fitted with SAS PROC MIXED will be used with vari-
ance weight 1/Nit where Nit is the observed number of
patients in the i-th practice at the t-th month.
Statistical power
Statistical power for the primary hypotheses is simulated
using model (3) with β1 = β12 = 0 and dropping g1(t;ψ)
from the model. It is based on a planned constant
sample size (denominator) of N = 200 patients/practice
at each time point. For the communication outcome, we
assumed β0 = 1.4 corresponding to a baseline rate of
80 % for a low ready practice (Xi2 = 0). For the shared
decision-making outcome, we set β0 = −0.8 giving 30 %
baseline when Xi2 = 0. Finally, we fixed β2 = 0.05 and
β3 = 0.05, variances σ0
2 = 0.42 and σ1
2 = 0.32, and covari-
ance σ01 = −0.15. These values for variance components
are adopted from Aim 1 for lack of preliminary data for
Aim 2. They are considered reasonable estimates because
the statistical analysis for Aim 2 involves a random effects
logistic regression model for repeated binomial data.
Power exceeds 98 % for detecting differences as small as
0.04 in proportions between intervention and control (see
Additional file 2).
Aim 3: Examine the effect of primary care practice support
on implementation of clinical practice and office system
changes that support delivery evidence-based CVD
prevention
Our primary hypothesis is that primary care practice
support will increase implementation of clinical practice
and office system changes to improve evidence-based
CVD prevention. Our secondary hypotheses are that (a)
primary care practice support intensity will increase
implementation of clinical practice and office system
changes, and (b) practice capacity for QI, organizational
readiness to implement change, and contextual factors
will moderate the effect of primary care practice support
on the implementation of clinical practice and office
system changes. We will explore the acceptability of pri-
mary care practice support from the perspective of the
provider champion.
Statistical analysis
A random coefficients linear mixed model will be ap-
plied to the KDIS based on practice facilitator ratings
collected monthly throughout the intervention period:
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E Y itj bi0; bi1ð Þ ¼ β0 þ bi0 þ β1X i1 þ β2X i2
þ β12X i1X i2 þ g1 t;ψð Þ
þ bi1t þ g2 t; λð Þ X it3 ð4Þ
where the explanatory variables and parameters are de-
fined as in model (1). In particular, Xit3 = 1 for all t = si +
1,…,si + 12, and g2(t; λ) is function for four piecewise
conjoined linear segments each of 3 months duration in
the intervention period with λ being the vector of slope
parameters, which we expect to be positive indicating an
increase in the number of clinical practice and office sys-
tem changes with an increase in the amount of imple-
mentation support. The main hypothesis is an overall
positive change in expected outcome between 12 months
post-intervention and 1 month post-intervention. The
first secondary hypothesis is that primary care practice
support intensity (with Xit3 re-defined and scaled as a
continuous measure ranging from 0 to 1) will be posi-
tively associated with the KDIS scale Yit. The second sec-
ondary hypothesis will assess practice capacity for QI,
organizational readiness to implement change, and con-
textual factors as effect modifiers on the rates of imple-
mentation given by g2(t; λ).
Statistical power
Power is simulated using a mixed effects linear model
similar to model (4) for the KDIS scale with β1 = β12 = 0
and dropping g1(t;ψ) giving an assumption for simplicity
of no secular trend:
E Y itj bi0; bi1ð Þ ¼ β0 þ bi0 þ β2X i2 þ bi1t
þ β3X it3 ð5Þ
with Xit3 = (t-1)/3 for t = 1, 2, 3, and 4. Model (5) dif-
fers from model (4) in that we model 3-month aver-
ages of KDIS scales producing quarterly data, in
accordance with preliminary data reported in Figure 2
of Halladay et al., which is as follows: electronic health
record (mean 2.78, sd = 3.17); care protocols (mean 1.71,
sd = 4.37); planned care (mean 2.16, sd = 3.84); and self-
management support (mean = 1.38, 3.67). It follows their
variances are 10, 19.1, 14.7, and 13.5, respectively [15].
Model (5) assumes that the intervention effect on KDIS is
linear in time during the yearlong implementation period;
under this model, the main hypothesis is an overall posi-
tive change in expected outcome between 12 months
post-intervention and 3 months post-intervention (β3 > 0).
For power calculations, we set β0 = 2, β2 = 0.5, β3 = 1.0,
σ0
2 = 5 (or 8), σ1
2 = 4, σ01 = −2 and σe
2 = 5 (or 8). Then,
under the random coefficients model, Var(Yit) = σ0
2 + σ1
2t2
+ 2 t σ01 + σe
2. Additional file 3 shows that power to show
an effect of intervention on KDIS scales exceeds 85 %
under the assumptions.
Supplemental analysis
We will use simple statistics to describe the frequency
and distribution of positively and negatively coded com-
ments about the acceptability of primary care practice
support. We will examine whether acceptability varied
by primary care practice support intensity, baseline cap-
acity for QI, and inner and outer contextual features.
We will use the qualitative data to explore the reasons
why KIs found primary care practice support acceptable
(or not) and recommendations they have for future
efforts.
Aim 4: Evaluate the effect of practice facilitation on practice
capacity to implement future evidence-based clinical
guidelines
Our primary hypothesis is that primary care practice
support will improve capacity to implement other
evidence-based clinical guidelines in the future. Our
secondary hypotheses are that (a) contextual factors
will moderate the effect of primary care practice sup-
port on practice capacity to implement additional
evidence-based clinical guidelines, and (b) primary
care practice support will generate additional positive
practice outcomes.
Statistical analysis
We will analyze adaptive reserve and change process
capability with a linear mixed model applied to the mea-
sures collected at baseline (t = si), at the end of the inter-
vention period (t = si + 12), and, for the early enrolled
practices, at 6 months post-intervention (t = si + 18). The
model to assess improvement in these outcomes is a
simplification of model (1) because there are only two
repeated outcomes:
E Y itj bi0;bi1
  ¼ β0 þ bi0 þ β1X i1 þ β2X i2
þ β12X i1X i2 þ g1 t;ψð Þ
þ bi1t þ β3X it3 þ β4X it4 ð6Þ
where Xit3 = 1 if t = si + 12 (end-of-intervention period)
and Xit3 = 0 otherwise; Xit4 = 1 if t = si + 18 (6 months
post-intervention) and baseline is the reference time
period. Other assumptions are as in model (4). Primary
interest is in β3, the difference in mean measure between
baseline and end-of-intervention period.
In secondary analyses, contextual factors will be exam-
ined as additional main effects and as statistical interac-
tions with Xit3 in order to assess whether there are effect
modifiers for the effect of primary care practice support
on practice capacity to implement future evidence-based
clinical guidelines. To test the hypothesis that primary
care practice support generated additional positive prac-
tice outcomes, we will calculate 95 % confidence inter-
vals for proportions of practices reporting positive
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outcomes, both overall and stratified by practice charac-
teristics (inner context). We will also use logistic regres-
sion to ascertain whether additional positive outcomes
varied as a function of primary care practice support in-
tensity, KDIS scores, ABCS measures, and inner context
variables.
Statistical power
For the primary hypotheses, we conservatively calculate
power by ignoring any information from individuals
6 months post-intervention and allow a 15 % dropout
(N = 255). Additional file 4 shows that our minimal de-
tectable differences are similar to mean change reported
by Nutting et al. and Solberg et al., respectively, for
adaptive reserve and CPCQ [10, 11].
Supplemental analysis
We will explore the reasons why some practices bene-
fited more than others by identifying themes about ac-
tions taken, missed opportunities, influential inner and
outer contextual factors, and other situational factors.
Trial status
Practices are being recruited. The high-readiness prac-
tices randomized to start in month 9 will receive the
intervention beginning January 2016.
Discussion
Significance
Practice facilitation, when combined with other quality
improvement interventions, is an effective strategy for
supporting the implementation of evidence-based guide-
lines in primary care settings [21]. However, no previous
effort has conducted a controlled trial of practice facili-
tation at the scale or level of intensity that we propose.
Results will have significant implications for healthcare
payers, government agencies, and other stakeholders
seeking to use practice facilitation, alone or combined
with other quality improvement interventions, to sup-
port national initiatives to scale up and spread evidence-
based clinical guidelines.
Limitations
Recruiting and retaining a large number of practices to
engage in a yearlong, comprehensive quality improvement
effort poses significant challenges. Potential recruitment
barriers include fear of financial risk, reluctance to share
data, acquisition by larger health systems, and competing
priorities. Potential retention barriers include loss of a key
clinician, resignation of a practice manager, and financial
difficulties. We will attempt to mitigate these barriers by
using practice facilitation to help practice achieve other
goals (e.g., PCMH recognition) or enhance billing for ser-
vices. Also, CCNC and AHEC will leverage their strong
relationships with hospitals and health systems to boost
recruitment and prevent attrition.
Our stepped-wedge study design affords some control
of the effects of secular trends and other factors unrelated
to our comprehensive quality improvement strategy. We
will supplement this by documenting and including in our
statistical analysis temporal events that could affect the
implementation and outcomes of the strategy. However,
the effects of outer context factors can be challenging to
measure and model.
Impact
If successful, our comprehensive quality improvement
strategy will have a positive impact on both practices and
patients. Hundreds of small- to medium-sized primary
care practices, many located in rural and medically under-
served areas, will be better prepared for the transition to
value-based payment, wherein an increasing proportion of
reimbursement is tied to performance on quality of care
measures. Likewise, discernible reductions in cardiovascu-
lar risk among the estimated 900,000 adult patients served
by participating practices would likely prevent thousands
of cardiovascular events within 10 years.
Additional files
Additional file 1: P+ower to detect difference in blood pressure
control between intervention and control condition (β3 )with
two-sided α = 5.0 % GLMM Wald significance test based on 300
practices and 200 simulations.
Additional file 2: Power to detect difference in proportions (Δ) of
patients for the two primary patient-level health outcomes between
the intervention after 12 months of implementation and the control
condition, two-sided α = 0.05, GLMM Wald significance test based
on 200 patients/practice per time point in each of 300 practices.
Additional file 3: Power to detect difference in mean KDIS score
of 1.0 (i.e., β3=1) in a practice comparing the intervention after
12 months of implementation and the control condition with
two-sided α = 0.05 based on two-sided F-tests from linear mixed
model analysis assuming 300 practices and varying dropout rate
and variance.
Additional file 4: Minimum detectable change from baseline to end
of intervention for practice capacity measures, 80 % power, varying
assumption about intra-practice correlation (ρ) based on two-sided
α = .05 paired t test (N=255).
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